Market Data
Market Cap₹12,594.67 Cr.
52W High₹839.25
Current Price₹800.2
52W Low₹410.1
Down from 52W High4.7 %
Face Value₹2
Performance
ROCE15.4 %
ROE8.8 %
EPS (TTM)₹6.53
EPS Prev Qtr₹5.53
EPS Last Year₹2.66
EBITDA Qtr₹133.61 Cr.
Book Value₹211
Financial Health
Debt/Equity0.02
Debt/Profit0.25
Total Assets₹5,446.965 Cr.
Dividend Yield0.37 %
Promoter Holding75.26 %
Earning Power7.51 %
Valuation
Stock P/E42.01
Industry P/E33.81
Price to Book3.8
Price to Sales2.8
Graham Number₹300.43
Key Metrics
Face Value
₹2
About Akums Drugs & Pharmaceuticals Ltd
Healthcare · Pharmaceuticals
Akums Drugs & Pharmaceuticals Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹2. Market cap ₹12,594.67 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a manageable debt-to-equity ratio of 0.02, indicating low financial risk.
- The Return on Capital Employed (ROCE) is 15.4%, showing efficient use of capital.
- The promoter holding is 75.26%, suggesting strong control and alignment of interests.
Weaknesses
- The P/E ratio of 40.52 indicates that the stock may be overvalued relative to earnings.
- The Return on Equity (ROE) is 8.83%, which is relatively low and suggests limited profitability from shareholders' equity.
- The dividend yield is only 0.39%, indicating lower income generation for investors.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 1,017.53 | 1,159.59 | 1,157.87 | 1,166.63 |
| ↳ QoQ Growth | - | +14.0% | -0.1% | +0.8% |
| Expenses | 960.92 | 1,052.38 | 1,046.27 | 1,033.02 |
| Operating Profit | 56.61 | 107.21 | 111.6 | 133.61 |
| OPM % | 5.56% | 9.25% | 9.64% | 11.45% |
| Other Income | 32.37 | 34.33 | 35.3 | 30.38 |
| Interest | 23.3 | 23.74 | 23.89 | 24.76 |
| Depreciation | 37.86 | 39.65 | 40.12 | 41.07 |
| EBITDA | 94.47 | 146.86 | 151.72 | 174.68 |
| EBITDA Margin % | 9.28% | 12.66% | 13.1% | 14.97% |
| Profit Before Tax | 65.67 | 99.57 | 121.22 | 139.24 |
| Tax % | 34.99% | 32.03% | 32.89% | 27.48% |
| Net Profit | 42.7 | 67.67 | 81.34 | 100.98 |
| ↳ QoQ Growth | - | +58.5% | +20.2% | +24.1% |
| EPS | 2.66 | 4.33 | 5.53 | 6.53 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 30.62 | 30.621 |
| Reserves | 3016.39 | 3282.727 |
| Borrowings | 88.22 | 72.95 |
| Other Liabilities | 978.21 | 2060.67 |
| Total Liabilities | 4113.44 | 5446.965 |
| Fixed Assets | 1390.18 | 1456.53 |
| CWIP | 159.62 | 176.664 |
| Investments | 0.14 | 0.14 |
| Other Assets | 2563.5 | 3813.63 |
| Total Assets | 4113.44 | 5446.965 |
Cash Flows
| Mar 2026 | |
|---|---|
| Cash from Operating Activity | 1181.202 |
| Cash from Investing Activity | -930.268 |
| Cash from Financing Activity | 33.88 |
| Net Cash Flow | 284.814 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 75.26% | 75.26% | 75.26% | 75.26% |
| FIIs % | 2.28% | 1.15% | 1.37% | 1.91% |
| DIIs % | 9.28% | 14.41% | 14.35% | 13.44% |
| Public % | 5.01% | 5.51% | 5.34% | 5.57% |
| No. of Shareholders | 75,365 | 76,869 | 72,589 | 70,289 |
Major Shareholders (>1%)
- Akums Master Trust (sanjeev Jain And Sandeep Jain)Promoter and Promoter Group40.79%
- Sandeep JainPromoter and Promoter Group17.24%
- Sanjeev JainPromoter and Promoter Group17.23%
- Franklin India Opportunites FundPublic Shareholding4.19%
As of 2026-06-30View all shareholders →